Highland Capital Management LLC Makes New Investment in Insulet Corporation $PODD

Key Points

• Highland Capital Management LLC has made a new investment in Insulet Corporation, acquiring 4,708 shares valued at approximately $1,479,000.
• Insulet's stock has recently faced insider selling, with two senior vice presidents selling shares and reducing their ownership by 17% and 16% respectively.
• Several research analysts have updated their ratings on Insulet, with Goldman Sachs lowering its target price to $375.00 while others, like Canaccord Genuity, raised theirs to $399.00.

Highland Capital Management LLC acquired a new stake in Insulet Corporation (NASDAQ:PODD - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 4,708 shares of the medical instruments supplier's stock, valued at approximately $1,479,000.

A number of other hedge funds have also modified their holdings of the business. Inspire Investing LLC boosted its stake in Insulet by 299.5% during the 1st quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier's stock worth $1,082,000 after purchasing an additional 3,088 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in shares of Insulet by 55.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock worth $1,376,000 after buying an additional 1,867 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Insulet by 1.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier's stock valued at $152,130,000 after acquiring an additional 10,628 shares during the period. Gradient Investments LLC acquired a new position in Insulet in the 2nd quarter valued at about $17,429,000. Finally, Vident Advisory LLC purchased a new stake in Insulet during the 1st quarter valued at approximately $216,000.

Insider Buying and Selling

In related news, SVP Laetitia Cousin sold 797 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Prem Singh sold 687 shares of the business's stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares of the company's stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on PODD shares. The Goldman Sachs Group dropped their target price on Insulet from $399.00 to $375.00 and set a "buy" rating on the stock in a report on Wednesday, October 1st. Canaccord Genuity Group lifted their price objective on shares of Insulet from $353.00 to $399.00 and gave the company a "buy" rating in a research report on Monday, September 29th. Wells Fargo & Company upped their price objective on shares of Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. Citigroup restated a "buy" rating on shares of Insulet in a research note on Tuesday, July 8th. Finally, Jefferies Financial Group reiterated a "buy" rating on shares of Insulet in a research note on Thursday, August 7th. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $346.83.

Insulet Stock Down 1.0%

Shares of NASDAQ:PODD opened at $309.11 on Monday. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $21.76 billion, a P/E ratio of 93.95, a P/E/G ratio of 2.57 and a beta of 1.40. Insulet Corporation has a 52-week low of $225.37 and a 52-week high of $353.50. The stock's fifty day simple moving average is $321.34 and its 200-day simple moving average is $299.00.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. During the same quarter in the previous year, the company posted $0.55 EPS. The firm's revenue for the quarter was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities research analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.